<p>Ocular Therapeutix, Inc.（纳斯达克代码：OCUL - 获取免费报告）目前获得了 14 家覆盖该股票的券商一致推荐的 “适度买入” 评级，Marketbeat.com 报道称。一位股票研究分析师给予该股票卖出评级，一位给予持有评级，十二位给予买入评级。在过去一年中，发布报告的券商对该股票的平均 12 个月目标价为 22.5556 美元。</p>
<p>获取 <strong>Ocular Therapeutix</strong> 警报：</p>
<p>多家研究公司最近对 OCUL 发表了看法。Cowen 在 10 月 30 日的报告中重申了对 Ocular Therapeutix 股票的 “买入” 评级。Chardan Capital 在 12 月 9 日的报告中重申了 “买入” 评级，并对 Ocular Therapeutix 股票设定了 21.00 美元的目标价。Robert W. Baird 在 10 月 3 日的研究报告中将 Ocular Therapeutix 的目标价从 17.00 美元上调至 24.00 美元，并给予该股票 “跑赢大盘” 的评级。HC Wainwright 在 12 月 8 日的研究报告中将 Ocular Therapeutix 的目标价从 19.00 美元上调至 21.00 美元，并给予该公司 “买入” 评级。最后，Zacks Research 在 10 月 2 日的研究报告中将 Ocular Therapeutix 的评级从 “强烈卖出” 上调至 “持有”。</p>
<p><strong>阅读我们对 OCUL 的最新分析</strong></p>
<h2>Ocular Therapeutix 股票下跌 0.7%</h2>
<p>纳斯达克 OCUL 的股票在周一开盘时为 14.56 美元。该公司的速动比率为 7.78，流动比率为 7.85，债务股本比率为 0.27。该公司的市值为 31 亿美元，市盈率为-10.11，贝塔值为 0.96。Ocular Therapeutix 的 52 周最低价为 5.78 美元，52 周最高价为 16.44 美元。该公司的 50 日简单移动平均线为 12.01 美元，200 日简单移动平均线为 11.41 美元。</p>
<p>Ocular Therapeutix（纳斯达克代码：OCUL - 获取免费报告）最后一次公布季度财报是在 11 月 4 日，生物制药公司报告该季度每股收益为（0.37 美元），超出市场共识预期的（0.39 美元）0.02 美元。Ocular Therapeutix 的股本回报率为-86.33%，净利润率为-447.57%。该公司该季度的收入为 1454 万美元，而分析师预期为 1457 万美元。研究分析师预计 Ocular Therapeutix 在当前财政年度的每股收益为-0.98 美元。</p>
<h2>内部买卖</h2>
<p>在相关消息中，内部人士 Jeffrey S. Heier 在 10 月 2 日的交易中出售了 10,502 股公司的股票。股票以平均价格 11.04 美元出售，总价值为 115,942.08 美元。交易后，该内部人士直接持有 249,409 股公司股票，价值约为 2,753,475.36 美元。这代表其持股比例下降了 4.04%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。此外，内部人士 Peter Kaiser 在 10 月 2 日的交易中出售了 9,653 股公司的股票。该股票以平均价格 11.03 美元出售，总交易额为 106,472.59 美元。交易完成后，该内部人士直接持有 194,440 股公司的股票，价值约为 2,144,673.20 美元。这代表其持股比例下降了 4.73%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士共出售了 31,287 股公司股票，价值 359,784 美元。内部人士持有公司股票的比例为 2.30%。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近增加或减少了对公司的持股。Cantor Fitzgerald L. P.在第三季度购买了 Ocular Therapeutix 的新股份，价值约 236 万美元。CIBC Bancorp USA Inc.在第三季度购买了 Ocular Therapeutix 的新股份，价值约 17.5 万美元。Maven Securities LTD 在第三季度购买了 Ocular Therapeutix 的新股份，价值约 116.9 万美元。Second Line Capital LLC 在第三季度将其在 Ocular Therapeutix 的持股增加了 4.4%。Second Line Capital LLC 现在持有 402,467 股该生物制药公司的股票，价值 470.5 万美元，此前在上个季度又购买了 17,000 股。最后，加拿大人寿保险公司在第三季度将其在 Ocular Therapeutix 的持股增加了 17.4%。加拿大人寿保险公司现在持有 31,914 股该生物制药公司的股票，价值 40 万美元，此前在上个季度又购买了 4,729 股。机构投资者持有公司 59.21% 的股票。</p>
<h2>Ocular Therapeutix 公司简介</h2>
<p>（获取免费报告）</p>
<p>Ocular Therapeutix, Inc.是一家生物制药公司，专注于在美国使用其生物可吸收水凝胶基配方技术开发、开发和商业化眼部疾病和状况的治疗。该公司市场上销售 DELTENZA，一种用于治疗眼科手术后眼部炎症和疼痛的地塞米松眼用插入物，以及过敏性结膜炎。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票比 Ocular Therapeutix 更好</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入游戏</li>
<li>如何计算期权利润</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>什么是股息冠军？如何投资于冠军</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NVTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NVTA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Ocular Therapeutix 吗？</h2>
<p>在考虑 Ocular Therapeutix 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Ocular Therapeutix 并不在名单上。</p>
<p>虽然 Ocular Therapeutix 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OCUL

<p>Ocular Therapeutix, Inc.（纳斯达克代码：OCUL）获得了 14 家券商的 “适度买入” 共识评级，12 个月的平均目标价为 22.56 美元。该股票的 52 周价格区间为 5.78 美元至 16.44 美元。近期注意到内部人士的股票出售和机构投资。公司报告的季度每股亏损为 0.37 美元，略好于预期，收入为 1454 万美元。内部人士持有该股票的 2.30%，而机构投资者持有 59.21%</p>

<p>Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has earned a consensus recommendation of &#34;Moderate Buy&#34; from the fourteen brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $22.5556.</p>
<div class="lb-trans"><p>Ocular Therapeutix, Inc.（纳斯达克代码：OCUL - 获取免费报告）目前获得了 14 家覆盖该股票的券商一致推荐的 “适度买入” 评级，Marketbeat.com 报道称。一位股票研究分析师给予该股票卖出评级，一位给予持有评级，十二位给予买入评级。在过去一年中，发布报告的券商对该股票的平均 12 个月目标价为 22.5556 美元。</p>
</div><p>Get <strong>Ocular Therapeutix</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ocular Therapeutix</strong> 警报：</p>
</div><p>A number of research firms recently weighed in on OCUL. Cowen reaffirmed a &#34;buy&#34; rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Chardan Capital reaffirmed a &#34;buy&#34; rating and issued a $21.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 9th. Robert W. Baird increased their price objective on Ocular Therapeutix from $17.00 to $24.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, October 3rd. HC Wainwright lifted their price objective on Ocular Therapeutix from $19.00 to $21.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, December 8th. Finally, Zacks Research upgraded Ocular Therapeutix from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, October 2nd.</p>
<div class="lb-trans"><p>多家研究公司最近对 OCUL 发表了看法。Cowen 在 10 月 30 日的报告中重申了对 Ocular Therapeutix 股票的 “买入” 评级。Chardan Capital 在 12 月 9 日的报告中重申了 “买入” 评级，并对 Ocular Therapeutix 股票设定了 21.00 美元的目标价。Robert W. Baird 在 10 月 3 日的研究报告中将 Ocular Therapeutix 的目标价从 17.00 美元上调至 24.00 美元，并给予该股票 “跑赢大盘” 的评级。HC Wainwright 在 12 月 8 日的研究报告中将 Ocular Therapeutix 的目标价从 19.00 美元上调至 21.00 美元，并给予该公司 “买入” 评级。最后，Zacks Research 在 10 月 2 日的研究报告中将 Ocular Therapeutix 的评级从 “强烈卖出” 上调至 “持有”。</p>
</div><p><strong>Read Our Latest Analysis on OCUL</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 OCUL 的最新分析</strong></p>
</div><h2>Ocular Therapeutix Stock Down 0.7%</h2>
<div class="lb-trans"><h2>Ocular Therapeutix 股票下跌 0.7%</h2>
</div><p>Shares of NASDAQ OCUL opened at $14.56 on Monday. The company has a quick ratio of 7.78, a current ratio of 7.85 and a debt-to-equity ratio of 0.27. The company has a market cap of $3.10 billion, a P/E ratio of -10.11 and a beta of 0.96. Ocular Therapeutix has a 52 week low of $5.78 and a 52 week high of $16.44. The business has a 50-day simple moving average of $12.01 and a two-hundred day simple moving average of $11.41.</p>
<div class="lb-trans"><p>纳斯达克 OCUL 的股票在周一开盘时为 14.56 美元。该公司的速动比率为 7.78，流动比率为 7.85，债务股本比率为 0.27。该公司的市值为 31 亿美元，市盈率为-10.11，贝塔值为 0.96。Ocular Therapeutix 的 52 周最低价为 5.78 美元，52 周最高价为 16.44 美元。该公司的 50 日简单移动平均线为 12.01 美元，200 日简单移动平均线为 11.41 美元。</p>
</div><p>Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.02. Ocular Therapeutix had a negative return on equity of 86.33% and a negative net margin of 447.57%.The firm had revenue of $14.54 million for the quarter, compared to analysts' expectations of $14.57 million. Research analysts anticipate that Ocular Therapeutix will post -0.98 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Ocular Therapeutix（纳斯达克代码：OCUL - 获取免费报告）最后一次公布季度财报是在 11 月 4 日，生物制药公司报告该季度每股收益为（0.37 美元），超出市场共识预期的（0.39 美元）0.02 美元。Ocular Therapeutix 的股本回报率为-86.33%，净利润率为-447.57%。该公司该季度的收入为 1454 万美元，而分析师预期为 1457 万美元。研究分析师预计 Ocular Therapeutix 在当前财政年度的每股收益为-0.98 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, insider Jeffrey S. Heier sold 10,502 shares of the company's stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $11.04, for a total value of $115,942.08. Following the transaction, the insider directly owned 249,409 shares in the company, valued at approximately $2,753,475.36. This represents a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, insider Peter Kaiser sold 9,653 shares of the business's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $11.03, for a total transaction of $106,472.59. Following the completion of the transaction, the insider directly owned 194,440 shares of the company's stock, valued at approximately $2,144,673.20. This represents a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 31,287 shares of company stock worth $359,784. Insiders own 2.30% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Jeffrey S. Heier 在 10 月 2 日的交易中出售了 10,502 股公司的股票。股票以平均价格 11.04 美元出售，总价值为 115,942.08 美元。交易后，该内部人士直接持有 249,409 股公司股票，价值约为 2,753,475.36 美元。这代表其持股比例下降了 4.04%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。此外，内部人士 Peter Kaiser 在 10 月 2 日的交易中出售了 9,653 股公司的股票。该股票以平均价格 11.03 美元出售，总交易额为 106,472.59 美元。交易完成后，该内部人士直接持有 194,440 股公司的股票，价值约为 2,144,673.20 美元。这代表其持股比例下降了 4.73%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士共出售了 31,287 股公司股票，价值 359,784 美元。内部人士持有公司股票的比例为 2.30%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the company. Cantor Fitzgerald L. P. purchased a new stake in Ocular Therapeutix during the third quarter valued at about $2,360,000. CIBC Bancorp USA Inc. bought a new position in shares of Ocular Therapeutix during the 3rd quarter valued at about $175,000. Maven Securities LTD purchased a new position in shares of Ocular Therapeutix during the 3rd quarter valued at about $1,169,000. Second Line Capital LLC raised its holdings in shares of Ocular Therapeutix by 4.4% during the 3rd quarter. Second Line Capital LLC now owns 402,467 shares of the biopharmaceutical company's stock valued at $4,705,000 after buying an additional 17,000 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its position in Ocular Therapeutix by 17.4% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 31,914 shares of the biopharmaceutical company's stock worth $400,000 after buying an additional 4,729 shares during the last quarter. Institutional investors own 59.21% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对公司的持股。Cantor Fitzgerald L. P.在第三季度购买了 Ocular Therapeutix 的新股份，价值约 236 万美元。CIBC Bancorp USA Inc.在第三季度购买了 Ocular Therapeutix 的新股份，价值约 17.5 万美元。Maven Securities LTD 在第三季度购买了 Ocular Therapeutix 的新股份，价值约 116.9 万美元。Second Line Capital LLC 在第三季度将其在 Ocular Therapeutix 的持股增加了 4.4%。Second Line Capital LLC 现在持有 402,467 股该生物制药公司的股票，价值 470.5 万美元，此前在上个季度又购买了 17,000 股。最后，加拿大人寿保险公司在第三季度将其在 Ocular Therapeutix 的持股增加了 17.4%。加拿大人寿保险公司现在持有 31,914 股该生物制药公司的股票，价值 40 万美元，此前在上个季度又购买了 4,729 股。机构投资者持有公司 59.21% 的股票。</p>
</div><h2>Ocular Therapeutix Company Profile</h2>
<div class="lb-trans"><h2>Ocular Therapeutix 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.</p>
<div class="lb-trans"><p>Ocular Therapeutix, Inc.是一家生物制药公司，专注于在美国使用其生物可吸收水凝胶基配方技术开发、开发和商业化眼部疾病和状况的治疗。该公司市场上销售 DELTENZA，一种用于治疗眼科手术后眼部炎症和疼痛的地塞米松眼用插入物，以及过敏性结膜炎。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Ocular Therapeutix</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>How to Calculate Options Profits</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Ocular Therapeutix 更好</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入游戏</li>
<li>如何计算期权利润</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>什么是股息冠军？如何投资于冠军</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NVTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OCUL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ocular Therapeutix Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Ocular Therapeutix 吗？</h2>
</div><p>Before you consider Ocular Therapeutix, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ocular Therapeutix 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocular Therapeutix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Ocular Therapeutix 并不在名单上。</p>
</div><p>While Ocular Therapeutix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ocular Therapeutix 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ocular Therapeutix, Inc.（NASDAQ: OCUL）被分析师给予 “适度买入” 的平均评级